Nedocromil sodium given by the Fisonair spacer should be inhaled immediately.
In the delivery of drugs to the respiratory tract, spacer devices are used to reduce the need to coordinate inhalation and metered dose inhaler (MDI) actuation. Optimum spacer use could improve the effectiveness of asthma management and reduce the waste of drugs which result from poor inhaler and spacer technique.'
This study determined the effect of multiple actuations of nedocromil sodium MDI ( In the first experiment a standard MDI of nedocromil sodium (2 mg per actuation) was connected to the impinger by a small plastic sock and the MDI discharged into the MSLI. With the Fisonair spacer device the MDI was actuated into the device and the device immediately attached to the MSLI.
To assess the effect of residency time, the Fisonair was held adjacent to the MSLI for five, 10, or 20 seconds after MDI actuation and then attached to the MSLI. The Fisonair was positioned so that aerosol would not be drawn into the MSLI before attachment.
To assess the effect of multiple actuations into the spacer, the procedure was repeated with the MDI actuated two or three times into the Fisonair before attaching it to the MSLI.
For all of the above experiments, the aerosol was discharged through the impinger up to 12 times to facilitate the drug assay, with one minute between each actuation. Before each actuation the MDI was shaken for 10 seconds or more. Each experiment was repeated four times, and the temperature, relative humidity, and barometric pressure were recorded. The flow through the MSLI was 60±2 litres per minute.
The size distribution of the aerosol cloud was determined from the amount of drug recovered from each stage, the MSLI having been previously calibrated with an aerosol of known particle size distribution. 
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Mean temperature was 22-9°C (range 21-23-5), mean barometric pressure was 996-7 mm Hg (range 985-1007-2), and the mean relative humidity was 50-5% (range 49-61).
Discussion
Nedocromil sodium is an effective antiinflammatory agent used in the treatment of asthma.3 Those unable to coordinate inhalation and inhaler actuation due to age or disability will need to use a spacer such as the Fisonair.
We have shown that a short delay between actuation of the MDI and inhalation reduces the amount of drug in small particles considerably. The reduction in available drug with time will be more important for those who take small breaths, taking a longer time to clear the spacer. Those administering the drug to another should take care to actuate the MDI when the patient is ready.
Multiple actuations of the MDI also decrease the amount of drug recovered in respirable particles. Later actuations may cause turbulent deposition of particles onto the spacer walls. The higher concentration of particles with multiple actuations may make collisions and agglomerations more likely, increasing particle size.
Knowledge of the actual dose available for inhalation allows meaningful comparison with other drug delivery methods.
This study confirms the work of others into multiple dosing with sodium cromoglycate2 4 5 and radioactive tracer.6 However, different drug formulations and spacer devices have different physical and electrostatic properties, so that findings of one study may not be applicable to other drugs and devices.
For the administration of nedocromil sodium, use of the Fisonair spacer device increases the amount of drug available for inhalation in respirable particles provided it is inhaled immediately after actuation of the MDI, and multiple actuations into the Fisonair are avoided.
